Pursuant to the Regulation 30 of the of the Securities and Exchange Board of India (‘SEBI’) (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’), Sudeep Pharma has informed that John Garcia (Vice President - Sales & Supply Chain) of Sudeep Pharma USA Inc, designated as SMP, vide his letter dated 4th February 2026 has tendered his resignation with effect from the close of business hours on 6th February, 2026. The requisite disclosure as required as per the requirement of Regulation 30 read with clause 7C of Part A of Schedule III of the Listing Regulations, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023 enclosed as AnnexureA. A copy of the said resignation letter is enclosed as Annexure-B. The above information is also being made available at the Company’s website at https://www.sudeeppharma.com/.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1652.00 |
| Dr. Reddys Lab | 1235.20 |
| Cipla | 1211.30 |
| Zydus Lifesciences | 923.10 |
| Lupin | 2312.35 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: